-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CDK4/6, namely cyclin-dependent kinases 4 and 6, is a key regulator of the cell division cycle.
A large number of clinical research data show that CDK4/6 inhibitors can significantly improve the progression-free survival (PFS), overall survival (OS) and quality of life of HR+/HER2- breast cancer patients.
At present, four CDK4/6 inhibitors have been approved globally, namely Pfizer’s Ibrance (palbociclib, piperacillin), Novartis’s Kisqali (Ribociclib, Ribociclib), Eli Lilly’s Verzenio (Abemaciclib, abeciclib) and G1 Therapeutics’ Cosela (trilaciclib).
The above three CDK4/6 inhibitors approved for the treatment of HR+/HER2- breast cancer have not been studied head-to-head, and it is impossible to compare which has the best treatment effect.
In addition, Verzenio is the first CDK4/6 inhibitor to be shown to statistically significantly reduce the risk of cancer recurrence in HR+/HER2-high-risk early breast cancer patients.
According to the financial reports of various companies, Ibrance has dazzled sales by virtue of its first-mover advantage.
CDK4/6 inhibitors, as the rising anti-cancer "magic drug" in recent years, are rapidly changing the treatment pattern of HR+/HER2- advanced breast cancer, effectively overcoming or delaying the emergence of endocrine resistance, and striving for more for advanced patients Survival time.
